This article was originally published in The Gray Sheet
Firm gains FDA clearance to market the Periflow angioplasty/infusion catheter for small vessel angioplasty and infusion of contrast media to "remote, difficult-to-reach locations." Limited shipments of the device, which employs CVD's multiple microporous membrane technology, are slated to begin in late 1994 following completion of clinicals in the U.S. and Europe
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.